
3852.ai applies AI-driven design to create combination therapies for hard-to-treat diseases. It relies on predictive AI, automated design of experiments, and robotics to identify and test treatment combinations. The company operates in biotech and pharmaceutical R&D, serving research labs and drug developers. Based in New York, it aims to scale across clinical research workflows and enable faster discovery.

3852.ai applies AI-driven design to create combination therapies for hard-to-treat diseases. It relies on predictive AI, automated design of experiments, and robotics to identify and test treatment combinations. The company operates in biotech and pharmaceutical R&D, serving research labs and drug developers. Based in New York, it aims to scale across clinical research workflows and enable faster discovery.